Related Experiment Video
Updated: May 29, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin as a geroprotector
1Ghent University, Ghent, Belgium. sven.bulterijs@ugent.be
Rejuvenation Research
|September 3, 2011
Summary
Metformin, a potential geroprotector, may slow aging. This review explores the evidence and mechanisms behind metformin's life-extending effects, investigating its role in aging research.
Area of Science:
- Gerontology and aging research.
- Pharmacology of aging.
- Cellular and molecular mechanisms of aging.
Background:
- Geroprotectors are substances that reduce aging rates and extend lifespan.
- Metformin is recognized as a potential geroprotector, with studies indicating it can slow aging.
- The precise mechanisms underlying metformin's geroprotective properties require further elucidation.
Purpose of the Study:
- To review the existing evidence supporting metformin's geroprotective effects.
- To elucidate the potential molecular and cellular mechanisms responsible for metformin's anti-aging actions.
- To consolidate current knowledge on metformin as an intervention for age-related decline.
Main Methods:
- Comprehensive literature search of preclinical and clinical studies on metformin and aging.
- Analysis of studies investigating metformin's impact on aging biomarkers and lifespan.
- Review of research exploring metformin's effects on cellular pathways relevant to aging.
Main Results:
- Evidence suggests metformin can indeed slow the aging process across various models.
- Multiple proposed mechanisms include modulation of cellular metabolism, inflammation, and stress resistance pathways.
- Studies indicate metformin's potential to improve healthspan alongside lifespan.
Conclusions:
- Metformin demonstrates significant promise as a geroprotector.
- Further research into its mechanisms will refine its application in aging interventions.
- Metformin represents a key area of investigation for extending human healthspan.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...